Sessa Maurizio, di Mauro Gabriella, Mascolo Annamaria, Rafaniello Concetta, Sportiello Liberata, Scavone Cristina, Capuano Annalisa
Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Section of Pharmacology "L. Donatelli", Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Front Pharmacol. 2018 Jun 12;9:611. doi: 10.3389/fphar.2018.00611. eCollection 2018.
The aim of this study is to investigate if following the implementation of the Regulation EU/1235/2010 and the Directive 2010/84/EU there was an increase of individual case safety reports (ICSRs) deriving from a medication error, abuse, misuse, overdose, or occupational exposure. Other objectives are the identification of drugs mostly involved in such cases, to establish if the codification of aforementioned conditions is performed correctly and, whenever codification errors exist, to identify predictors of codification errors. Finally, we estimated the magnitude of these errors on signal detection activities. ICSRs sent through Campania Region (Italy) spontaneous reporting system from July 2nd 2012 to December 31th 2017 were used as data source. A multivariable logistic regression model was used to identify predictors of codification errors. Four measures of disproportionality were used to investigate the magnitude of codification errors on a known safety signal or rather the association between benzodiazepines derivatives and abuse. In all, 358 (1.4%) out of 25610 ICSRs reported "non-normal use" of drugs, mainly as cases of abuse. Drugs mostly involved in abuse were "Benzodiazepines derivatives" (171/358; 47.8%). For medication errors instead, "Other antiseptics and disinfectants" (9/358; 2.5%). At the first quality control, 125 (34.9%) out of 358 ICSRs did not have a codification of "non-normal use" or codifications were performed wrongly. Codification errors included misclassification of abuse as overdose (10/125; 8.0%) and misclassification of medication error as overdose (7/125; 5.6%) or abuse (7/125; 5.6%). Compared to pharmaceutical companies, patients/citizens (as reporters) had a 24.88 higher odd (Reporting Odds Ratio 24.88, 95%CI 1.82-449.95; -value: 0.02) of performing un-classification or misclassification of aforementioned codifications. Codification errors were associated with the underestimation of measure of disproportionality' estimates in the identification of the safety signal "Benzodiazepine derivatives /abuse". In conclusion, this study found that in Campania Region (southern Italy) there was an exponential increase of ICSR reporting "non-normal use," mainly as cases of abuse, with an improvable proportion of cases misclassified/unclassified. Moreover, this study found that ICSRs sent by patients/citizens were associated with an increased odd of un-classification or misclassification that had a relevant impact on signal detection activities.
本研究的目的是调查在实施欧盟/1235/2010号法规和2010/84/EU号指令之后,因用药错误、滥用、误用、过量用药或职业暴露而产生的个体病例安全报告(ICSR)数量是否有所增加。其他目标包括确定此类病例中最常涉及的药物,确定上述情况的编码是否正确进行,以及在存在编码错误时,识别编码错误的预测因素。最后,我们估计了这些错误对信号检测活动的影响程度。通过意大利坎帕尼亚大区自发报告系统在2012年7月2日至2017年12月31日期间发送的ICSR被用作数据源。使用多变量逻辑回归模型来识别编码错误的预测因素。使用四种不成比例性度量方法来研究已知安全信号上编码错误的程度,或者更确切地说是苯二氮䓬类衍生物与滥用之间的关联。在总共25610份ICSR中,有358份(1.4%)报告了药物 “非正常使用”,主要是滥用情况。滥用中最常涉及的药物是 “苯二氮䓬类衍生物”(171/358;47.8%)。对于用药错误而言,“其他防腐剂和消毒剂”(9/358;2.5%)。在首次质量控制中,358份ICSR中有125份(34.9%)没有 “非正常使用” 的编码,或者编码错误。编码错误包括将滥用误分类为过量用药(10/125;8.0%)以及将用药错误误分类为过量用药(7/125;5.6%)或滥用(7/125;5.6%)。与制药公司相比,患者/公民(作为报告者)进行上述编码未分类或错误分类的可能性高24.88倍(报告比值比24.88,95%置信区间1.82 - 449.95;P值:0.02)。在识别 “苯二氮䓬类衍生物/滥用” 这一安全信号时,编码错误与不成比例性度量估计值的低估相关。总之,本研究发现,在意大利南部的坎帕尼亚大区,报告 “非正常使用”(主要是滥用情况)的ICSR呈指数增长,未分类/错误分类的病例比例有待改进。此外,本研究发现患者/公民发送的ICSR与未分类或错误分类的可能性增加相关,这对信号检测活动有重大影响。